Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05675696
Other study ID # 22-00695
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2024
Est. completion date June 1, 2025

Study information

Verified date April 2024
Source NYU Langone Health
Contact Beno Oppenheimer
Phone 917-797-2128
Email Beno.Oppenheimer@nyulangone.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study will utilize esophageal manometry to measure the presence and magnitude of persistent patient effort during lung protective ventilation, allowing identification and mitigation of occult lung stress.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date June 1, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Intubated with a diagnosis of ARDS and expected to be ventilated for = 48 hours - Meets Berlin criteria for ARDS, with or without underlying chronic lung disease - Triggering breaths on the ventilator - Treating medical team agrees with patient participation Exclusion Criteria: - Known or suspected esophageal abnormalities, craniofacial abnormalities, or upper GI bleed - Shock that requires = 2 vasopressors - pH on arterial blood gas =7.25 - Minute ventilation = 14L/min - Known or suspected pneumothorax, pneumomediastinum, and/or subcutaneous emphysema - Severe ARDS with P/F ratio <60 - Pregnancy - Currently receiving extracorporeal membrane oxygenation (ECMO) therapy - Decision to withhold life-sustaining treatment - Patients who are not expected to survive for 24 hours - Lack of informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Esophageal Catheter
Newly designed external monitor that will capture esophageal pressure from a proprietary nasogastric tube combined with simultaneous pressure, flow, and volume measurements from the ventilator tubing.

Locations

Country Name City State
United States Tisch Hospital New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transpulmonary Driving Pressure Transpulmonary driving pressure is the pressure difference between the airway opening and pleural surface. It represents lung stress and is higher with increased spontaneous respiration and work of breathing. Up to Hour 2 (Day 1)
Primary Driving Pressure Driving pressure is defined as plateau pressure minus positive end-expiratory pressure (PEEP). Driving pressure during mechanical ventilation is directly related to stress forces in the lung. Up to Hour 2 (Day 1)
Primary Work of Breathing (WOB) WOB is the amount of energy or oxygen (O2) consumption needed by the respiratory muscles to produce enough ventilation and respiration to meet the metabolic demands of the body. Up to Hour 2 (Day 1)
Primary Pressure-Time Product (PTP) PTP is the product of the average inspiratory pressure (starting from the onset of effort) and the duration of inspiration. The PTP was developed to account for energy expenditures during the dynamic and isometric phases of respiration. Up to Hour 2 (Day 1)
Secondary Lung Compliance (C, l) Lung compliance is calculated as the tidal volume divided by the difference of transpulmonary pressure at end inspiration minus transpulmonary pressure at PEEP:
(C, l) = tidal volume/(transpulmonary pressure at end inspiration - transpulmonary pressure at PEEP).
Expressed in (ml/cmH2O).
Up to Hour 2 (Day 1)
Secondary Chest Wall Compliance (C, cw) Chest wall compliance is calculated as the tidal volume divided by the difference of esophageal pressure at end inspiration minus esophageal pressure at PEEP:
(C, cw) = tidal volume/(esophageal pressure at end inspiration - esophageal pressure at PEEP).
Expressed in (ml/cmH2O).
Up to Hour 2 (Day 1)
Secondary Respiratory System Compliance (C, rs) Respiratory System Compliance is calculated as the tidal volume divided by the difference of the airway pressure at end inspiration minus airway pressure at PEEP:
(C, rs) = tidal volume/(airway pressure at end inspiration - airway pressure at PEEP).
Expressed in (ml/cmH2O).
Up to Hour 2 (Day 1)
Secondary Oxygen Saturation Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin in the blood. Up to Hour 2 (Day 1)
Secondary PaO2/FiO2 (P/F) Ratio The P/F ratio is the arterial partial pressure of oxygen (PaO2) divided by the inspired oxygen concentration (FiO2). Up to Hour 2 (Day 1)
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Completed NCT01504893 - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A